Moderate-to-severe atopic dermatitis patients show increases in serum C-reactive protein levels, correlating with skin disease activity.
| Autor: | Vekaria AS; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA., Brunner PM; The Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, 10065, USA., Aleisa AI; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA., Bonomo L; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA., Lebwohl MG; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA., Israel A; Department of Family Medicine, Clalit Health Services, Jerusalem, 954323, Israel., Guttman-Yassky E; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.; The Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, 10065, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | F1000Research [F1000Res] 2017 Sep 20; Vol. 6, pp. 1712. Date of Electronic Publication: 2017 Sep 20 (Print Publication: 2017). |
| DOI: | 10.12688/f1000research.12422.2 |
| Abstrakt: | Background : Atopic dermatitis (AD), the most common chronic inflammatory skin disease, is evolving as a systemic disease, and associated systemic inflammation is possibly linked to increases in cardiovascular disease. Methods : We assessed levels of the inflammatory marker CRP in 59 patients with moderate-to-severe AD compared to matched healthy controls, and to determine correlation with skin disease severity. Clinical severity was measured using SCORing of Atopic Dermatitis (SCORAD) and body surface area (BSA). Control subjects (n=118), matched by age, gender, smoking status and ethnicity, were obtained from the National Health and Nutrition Survey (NHANES). Results : AD patients had significantly increased serum CRP levels compared to controls (0.7±1.0 vs. 0.4±0.7mg/dl; p=0.001), and 52.5% of them showed CRP levels >0.3mg/dl, predicting high cardiovascular risk. CRP levels were significantly correlated with both SCORAD (r=0.427, p=0.0008) and BSA (r=0.407, p=0.0015). IgE levels in AD were highly elevated (median 2903U/ml, IQR [234,10655]), but only weakly correlated with SCORAD (r=0.282, p=0.0427) and BSA (r=0.382, p=0.0052), but not with CRP levels. AD patients also showed increased LDH levels, but without significant correlations with disease severity (SCORAD, BSA) or CRP. Conclusions : Our study strongly supports CRP as a marker for disease severity in moderate-to-severe AD patients, further demonstrating its chronic systemic nature. Competing Interests: Competing interests: PMB has received personal fees from LEO Pharma and Sanofi. EGY is a board member for Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Celsus, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae, Leo Pharma, Abbvie and Asana Biosciences; has received consultancy fees from Regeneron, Sanofi, MedImmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, LEO Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe, Eli Lilly, Abbvie, and Asana Biosciences; and has received research support from Janssen, Regeneron, Celgene, BMS, Novartis, Merck, LEO Pharma, Dermira, Glenmark, Innovaderm, and UCB. The rest of the authors declare that they have no relevant conflicts to disclose. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|